resolution to certify the financial statements and performance of the Company and the Company’s subsidiaries for the third quarter ending 30 September 2018, which has already been examined by the Company’s
quarter again on target. We met our key financial objectives, such as EBITDA and net income, despite a very weak sugar season, via launching commercial sales of a new product, extending the export markets
financial statements for the 3rd quarter of 2017 ending 30 September 2017, the Company would like to report factors that affect the financial performance for the 3rd quarter of 2017 as follows; Statements of
. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public
credit facilities with financial institutions. Utilization of funds from the issuance of newly issued ordinary shares as of September 30, 2024, is as follows: Purpose of fund utilization Budgeted amount
20230 โทรศพัท ์038 480 020-1 โทรสาร 038 480 080 620/5 Moo 11 Nongkham, Sriracha, Chonburi 20230 Tel. 66-38 480-020-1 FAX. 66-38 480-080 Separate financial statements Revenues 1. Dividend income 6.82
the consolidate financial statement has net loss 3.40 Million Baht, increase of 21.29 Million Baht or 119.01% comparing to the last year. Loss attributable to equity holders of the parent is 5.61
totaled THB 1,401.68 million or 1.67 percent. As a result of effective ownership transferring was increase. Rental income and service revenue The Company and its subsidiaries’ rental income and service
Associates 95.25 1.15 (58.59) (0.76) 153.84 262.58 Financial Costs (40.23) (0.48) (38.53) (0.50) 1.70 4.41 Profit before Income Taxes 684.32 8.23 486.35 6.31 197.97 40.70 Income Tax Expenses (111.31) (1.34
subsidiaries Explanation of the operating performance for the year 2017 as in the consolidate financial statement has net loss 38.31 Million Baht, decrease of 291.72 Million Baht or 115.12% comparing to the last